Nasdaq Biotechnology Ishares ETF (NQ: IBB )
126.17 -0.92 (-0.72%) Official Closing Price Updated: 4:15 PM EDT, May 30, 2023 Add to My Watchlist
All News about Nasdaq Biotechnology Ishares ETF
Stock Market Forecast: Stocks May Drop Further As Rates Rise
February 26, 2023
This week will be full of economic insights, but the big data will be the ISM manufacturing and services indexes. However, I think these two reports are unlikely to do much to reverse the current trend...
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to
Tarsus Added to NASDAQ Biotechnology Index
December 16, 2022
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 02, 2022
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs...
Exposures Product Safety US Equities
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 01, 2022
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following